EndoSign® for Barrett's Esophagus / Esophageal Neoplasia
Detection and risk stratification of Barrett's Esophagus and early esophageal neoplasia
CommercialActive
Key Facts
Indication
Detection and risk stratification of Barrett's Esophagus and early esophageal neoplasia
Phase
Commercial
Status
Active
Company
About Cyted Health
Cyted Health is a commercial-stage diagnostics company focused on revolutionizing the early detection of gastrointestinal diseases, particularly esophageal cancer and its precursor, Barrett's Esophagus. Its core technology is the EndoSign® capsule sponge, a minimally invasive device for cell collection, which is integrated with advanced molecular diagnostics. The company has achieved significant milestones including FDA 510(k) clearance, initiation of a major UK screening trial (BEST4), and a $44 million Series B financing round to accelerate US expansion.
View full company profile